Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia
Although eosinophilia has been reported as a side effect of purine analogues, there is no report on fludarabine-induced eosinophilia in chronic lymphocytic leukemia (CLL). During chemotherapy with fludarabine and cyclophosphamide, we observed two cases of significant eosinophilia. A 67-year-old pati...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 1999-10, Vol.78 (10), p.475-477 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 477 |
|---|---|
| container_issue | 10 |
| container_start_page | 475 |
| container_title | Annals of hematology |
| container_volume | 78 |
| creator | SEZER, O SCHMID, P HALLEK, M SCHWEIGERT, M BEINERT, T LANGELOTZ, C MERGENTHALER, H.-G POSSINGER, K |
| description | Although eosinophilia has been reported as a side effect of purine analogues, there is no report on fludarabine-induced eosinophilia in chronic lymphocytic leukemia (CLL). During chemotherapy with fludarabine and cyclophosphamide, we observed two cases of significant eosinophilia. A 67-year-old patient with CLL developed bone marrow and peripheral blood eosinophilia up to 7.9x10(9)/l, the highest eosinophil count ever reported during treatment with a purine analogue. The eosinophilia persisted for 33 days. Another patient developed bone marrow eosinophilia without eosinophilia in the peripheral blood. These are the first documented cases of fludarabine-induced eosinophilia in CLL, and this side effect may conceivably be more common than previously recognized. |
| doi_str_mv | 10.1007/s002770050602 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1464496872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2511575418</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-fc01eb28e0ee5b0a161c22fbbaac4d98c60a2978980e47d95403e02d0fe660493</originalsourceid><addsrcrecordid>eNpd0D1PwzAQBmALgaAURlYUCQaWwNmxE3tEVYFKlVhgjhznQl0Su9jJ0H9Pqlbi45a74dHd6SXkisI9BSgeIgArCgABObAjMqE8YykIyY_JBFSmUjHWGTmPcQ1AmeTslJxREAJEDhOymPtond-sbGt1Ug_Buo-kaYdaB11Zh0kfUPcduj7xTWJWwTtrknbbbVbebPvdjMMndlZfkJNGtxEvD31K3p_mb7OXdPn6vJg9LlOTUdqnjQGKFZMIiKICTXNqGGuqSmvDayVNDpqpQioJyItaCQ4ZAquhwTwHrrIpudvv3QT_NWDsy85Gg22rHfohlpTnnKtcFmykN__o2g_Bjd-VTFAqCsGpHFW6Vyb4GAM25SbYTodtSaHcZVz-yXj014etQ9Vh_UvvQx3B7QHoaHTbBO2MjT9OyfGqzL4BwIeCqQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2511575418</pqid></control><display><type>article</type><title>Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>SEZER, O ; SCHMID, P ; HALLEK, M ; SCHWEIGERT, M ; BEINERT, T ; LANGELOTZ, C ; MERGENTHALER, H.-G ; POSSINGER, K</creator><creatorcontrib>SEZER, O ; SCHMID, P ; HALLEK, M ; SCHWEIGERT, M ; BEINERT, T ; LANGELOTZ, C ; MERGENTHALER, H.-G ; POSSINGER, K</creatorcontrib><description>Although eosinophilia has been reported as a side effect of purine analogues, there is no report on fludarabine-induced eosinophilia in chronic lymphocytic leukemia (CLL). During chemotherapy with fludarabine and cyclophosphamide, we observed two cases of significant eosinophilia. A 67-year-old patient with CLL developed bone marrow and peripheral blood eosinophilia up to 7.9x10(9)/l, the highest eosinophil count ever reported during treatment with a purine analogue. The eosinophilia persisted for 33 days. Another patient developed bone marrow eosinophilia without eosinophilia in the peripheral blood. These are the first documented cases of fludarabine-induced eosinophilia in CLL, and this side effect may conceivably be more common than previously recognized.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s002770050602</identifier><identifier>PMID: 10550560</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Aged ; Agent Orange ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Blood diseases ; Bone marrow ; Drug toxicity and drugs side effects treatment ; Eosinophilia - chemically induced ; Humans ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Toxicity: blood ; Vidarabine - adverse effects ; Vidarabine - analogs & derivatives ; Vidarabine - therapeutic use</subject><ispartof>Annals of hematology, 1999-10, Vol.78 (10), p.475-477</ispartof><rights>1999 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1999.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-fc01eb28e0ee5b0a161c22fbbaac4d98c60a2978980e47d95403e02d0fe660493</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1981838$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10550560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SEZER, O</creatorcontrib><creatorcontrib>SCHMID, P</creatorcontrib><creatorcontrib>HALLEK, M</creatorcontrib><creatorcontrib>SCHWEIGERT, M</creatorcontrib><creatorcontrib>BEINERT, T</creatorcontrib><creatorcontrib>LANGELOTZ, C</creatorcontrib><creatorcontrib>MERGENTHALER, H.-G</creatorcontrib><creatorcontrib>POSSINGER, K</creatorcontrib><title>Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>Although eosinophilia has been reported as a side effect of purine analogues, there is no report on fludarabine-induced eosinophilia in chronic lymphocytic leukemia (CLL). During chemotherapy with fludarabine and cyclophosphamide, we observed two cases of significant eosinophilia. A 67-year-old patient with CLL developed bone marrow and peripheral blood eosinophilia up to 7.9x10(9)/l, the highest eosinophil count ever reported during treatment with a purine analogue. The eosinophilia persisted for 33 days. Another patient developed bone marrow eosinophilia without eosinophilia in the peripheral blood. These are the first documented cases of fludarabine-induced eosinophilia in CLL, and this side effect may conceivably be more common than previously recognized.</description><subject>Aged</subject><subject>Agent Orange</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood diseases</subject><subject>Bone marrow</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Eosinophilia - chemically induced</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Toxicity: blood</subject><subject>Vidarabine - adverse effects</subject><subject>Vidarabine - analogs & derivatives</subject><subject>Vidarabine - therapeutic use</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0D1PwzAQBmALgaAURlYUCQaWwNmxE3tEVYFKlVhgjhznQl0Su9jJ0H9Pqlbi45a74dHd6SXkisI9BSgeIgArCgABObAjMqE8YykIyY_JBFSmUjHWGTmPcQ1AmeTslJxREAJEDhOymPtond-sbGt1Ug_Buo-kaYdaB11Zh0kfUPcduj7xTWJWwTtrknbbbVbebPvdjMMndlZfkJNGtxEvD31K3p_mb7OXdPn6vJg9LlOTUdqnjQGKFZMIiKICTXNqGGuqSmvDayVNDpqpQioJyItaCQ4ZAquhwTwHrrIpudvv3QT_NWDsy85Gg22rHfohlpTnnKtcFmykN__o2g_Bjd-VTFAqCsGpHFW6Vyb4GAM25SbYTodtSaHcZVz-yXj014etQ9Vh_UvvQx3B7QHoaHTbBO2MjT9OyfGqzL4BwIeCqQ</recordid><startdate>19991001</startdate><enddate>19991001</enddate><creator>SEZER, O</creator><creator>SCHMID, P</creator><creator>HALLEK, M</creator><creator>SCHWEIGERT, M</creator><creator>BEINERT, T</creator><creator>LANGELOTZ, C</creator><creator>MERGENTHALER, H.-G</creator><creator>POSSINGER, K</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>19991001</creationdate><title>Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia</title><author>SEZER, O ; SCHMID, P ; HALLEK, M ; SCHWEIGERT, M ; BEINERT, T ; LANGELOTZ, C ; MERGENTHALER, H.-G ; POSSINGER, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-fc01eb28e0ee5b0a161c22fbbaac4d98c60a2978980e47d95403e02d0fe660493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Aged</topic><topic>Agent Orange</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood diseases</topic><topic>Bone marrow</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Eosinophilia - chemically induced</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Toxicity: blood</topic><topic>Vidarabine - adverse effects</topic><topic>Vidarabine - analogs & derivatives</topic><topic>Vidarabine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SEZER, O</creatorcontrib><creatorcontrib>SCHMID, P</creatorcontrib><creatorcontrib>HALLEK, M</creatorcontrib><creatorcontrib>SCHWEIGERT, M</creatorcontrib><creatorcontrib>BEINERT, T</creatorcontrib><creatorcontrib>LANGELOTZ, C</creatorcontrib><creatorcontrib>MERGENTHALER, H.-G</creatorcontrib><creatorcontrib>POSSINGER, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SEZER, O</au><au>SCHMID, P</au><au>HALLEK, M</au><au>SCHWEIGERT, M</au><au>BEINERT, T</au><au>LANGELOTZ, C</au><au>MERGENTHALER, H.-G</au><au>POSSINGER, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia</atitle><jtitle>Annals of hematology</jtitle><addtitle>Ann Hematol</addtitle><date>1999-10-01</date><risdate>1999</risdate><volume>78</volume><issue>10</issue><spage>475</spage><epage>477</epage><pages>475-477</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Although eosinophilia has been reported as a side effect of purine analogues, there is no report on fludarabine-induced eosinophilia in chronic lymphocytic leukemia (CLL). During chemotherapy with fludarabine and cyclophosphamide, we observed two cases of significant eosinophilia. A 67-year-old patient with CLL developed bone marrow and peripheral blood eosinophilia up to 7.9x10(9)/l, the highest eosinophil count ever reported during treatment with a purine analogue. The eosinophilia persisted for 33 days. Another patient developed bone marrow eosinophilia without eosinophilia in the peripheral blood. These are the first documented cases of fludarabine-induced eosinophilia in CLL, and this side effect may conceivably be more common than previously recognized.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>10550560</pmid><doi>10.1007/s002770050602</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 1999-10, Vol.78 (10), p.475-477 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1464496872 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Agent Orange Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Blood diseases Bone marrow Drug toxicity and drugs side effects treatment Eosinophilia - chemically induced Humans Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Toxicity: blood Vidarabine - adverse effects Vidarabine - analogs & derivatives Vidarabine - therapeutic use |
| title | Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T00%3A03%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eosinophilia%20during%20fludarabine%20treatment%20of%20chronic%20lymphocytic%20leukemia&rft.jtitle=Annals%20of%20hematology&rft.au=SEZER,%20O&rft.date=1999-10-01&rft.volume=78&rft.issue=10&rft.spage=475&rft.epage=477&rft.pages=475-477&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s002770050602&rft_dat=%3Cproquest_cross%3E2511575418%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2511575418&rft_id=info:pmid/10550560&rfr_iscdi=true |